Enhanced Protection with Inactivated Foot-and-Mouth Disease Virus Purified by a Tagged-Marker Expressing on Virus Surface Animal and Plant Quarantine Agency.

Slides:

Advertisements

Similar presentations

Step 1: Enzyme digest to remove stop codon from original plasmid Step 2: Mutagenesis PCR to remove stop codon Step 3: Mutagenesis PCR to remove 1071 G.

Advertisements

Immunogen vs Antigen immunogen induces immune response antigen reacts with products of the immune response immunogenicity –nature of the immunogen –ability.

IL-2 as the adjuvant in FMD vaccine Chunxia su ， ph.D. Ningxia Medical University Yinchuan ， China.

Purification of bioengineered proteins CPSC 265 Week 12.

Coimmunization of Agaricus blazei Murill extract with hepatitis B virus core protein through DNA vaccine enhances cellular and humoral immune responses.

Silvia Pellicer. WorldPathol S.L. (Spain)

Protein Purification. Why purify Proteins? Characterize Function Activity Structure Study protein regulation and protein interactions Use in assays Produce.

Monocolonial Antibody. IB Learning Objective Describe the production of monoclonal antibodies.

Vaccines Polio - close to eradication. In 2001 >1000 cases worldwide; last wild case in Americas in Peru in 1991.

Evaluation of avian influenza vaccines on commercial layer chicks M.M. Amer, Sherein, S.abdelgayed and Abeer, A. Abd El-Baky.

Preparation and Evaluation of an Inactivated Multi-Strain PRRS Vaccine Made with Viruses Isolated from Vietnam Central Vietnam Veterinary Institute This.

KEY CONCEPT Genetics provides a basis for new medical treatments.

Central Vietnam Veterinary Institute

Display of the Viral Epitopes on Lactococcus lactis: A Model for Food Grade Vaccine against EV71.

Influenza Vaccine Development

Foot and Mouth Disease Aphthous fever FMD الحمى القلاعية Foot and Mouth Disease Aphthous fever FMD الحمى القلاعية Bibliotheca Alexandrina 18/3/2012.

Edible Vaccines: eating our way to the eradication of disease.

FMD OUTBREAK: A Practical Example of Adressing Gaps in Control Strategy Dr Gaolathe Thobokwe Botswana Vaccine Institute.

Immunology ANTIBODIES we have ~10 12 antibodies made against foreign viruses, bacteria, parasites (vaccines) antibodies combine with foreign antigens to.

Supplementary Methods TEM (transmission electron microscopy). TEM analysis were performed on EF-TEM LEO 912AB (Carl Zeiss Inc., Germany, Korea Basic Science.

Viruses. Non-cellular particles of nucleic acid, protein, and in some cases lipids that can reproduce only by infecting living cells Differ widely in.

Microbial Biotechnology Philadelphia University

Investigating the Glycosylation of Interleukin 13 Receptor Alpha 2 Protein Expressed in Cancerous and Non-cancerous Cell Lines Christopher R. Pope and.

Antibodies Cells of the vertebrate acquired immune system produce antibodies with an exquisite specificity for molecules Biologists use antibodies to localize.

CHALLENGES FACED IN THE DEVELOPMENT OF BIOSIMILARS Dr.G.Hima Bindu MD; PG dip. diabetology Asst.Professor Dept. of Pharmacology Rajiv Gandhi Institute.

Construction of Plasmids & Purification of Core-Haemagglutinin VLPs.

Generation of mAbs to FMDV/A and application in a cELISA for the detection of FMDV/A antibodies Dr. M. Yang National Center for Foreign Animal diseases.

Chapter 12 Lecture Outline Molecular Techniques and Biotechnology.

The Purification and Characterization

Pandemic Vaccines Current and Future Issues 30 January 2007 Beijing Keiji Fukuda Global Influenza Programme.

FMD Vaccine Manufacture: Controls and Constraints

Bernd Haas 14 March 1958 – 4 October Replacement of FMDV cattle tongue titration by in-vitro titration Aldo Dekker.

DECEPTIVE IMPRINTING OF FMDV: MAPPING OF CAPSID HYPER-VARIABLE REGIONS BETWEEN TWO DISPARATE SAT2 STRAINS Tovhowani Ramulongo Lia Rotherham, Pamela Opperman,

Julian Seago Improving quality assurance of FMD vaccine production.

IDENTIFICATION, PURIFICATION AND CHARACTERIZATION OF PROTEINS FROM THE PROTECTIVE FRACTION (F0) OF Paracoccidioides brasiliensis Fernandes, V. C. 1 ; Reis,

Making Vaccines. Effective Vaccines Have low levels of side effects or toxicity. Protect against exposure to natural, or wild forms of the pathogen. Should.

Protein Purification for Crystallization Dr Muhammad Imran Forman Christian College (A Chartered University) Dr Muhammad Imran Forman Christian College.

9.4 Genetic Engineering Updates: Mutations practice due Homework: –Read 9.5 –Restriction enzymes cut sites/gel due tomorrow Unit 5 quiz 2 Thursday Keystone.

اختبارات التعادل المناعي:Neutralization Tests:

WHAT IS A VIRUS? A NONLIVING, NONCELLULAR PARTICLE MADE UP OF GENETIC MATERIAL AND PROTEIN.

Protein Overexpression in E. coli and

Recombinant Hormones and Drugs.  Many human disorders traced to absence or malfunction of a protein normally synthesized in the body  eg. Sickle cell.

Vaccine; To be effective  Must stimulate as many of the body's defence mechanisms as possible.  It is not necessary to get 100% uptake of vaccine in.

PHYSICO-CHEMICAL AND BIOLOGICAL PROPERTIES OF TYPE O FOOT AND MOUTH DISEASE STRAINS ISOLATED FROM SOUTH AMERICAN OUTBREAKS (2006 TO 2011) Galdo Novo S1,

Molecular Therapy - Methods & Clinical Development

DISCUSSION AND CONCLUSION

Volume 3, Issue 6, Pages (June 2001)

The secreted form of ORF2 (ORF2S) is glycosylated and dimerized.

Novel vaccine adjuvants for infectious diseases aninal

Edible Vaccines: eating our way to the eradication of disease

KEY CONCEPT Genetics provides a basis for new medical treatments.

Hours after rec PR-Set7 release Ladder kDa 15 PR-Set7 Coomassie

Vaccine Differentiation Group

A PRIME-BOOST VACCINATION STRATEGY IN CATTLE TO PREVENT SEROTYPE O FMDV INFECTION USING A “SINGLE-CYCLE” ALPHAVIRUS VECTOR AND EMPTY CAPSID PARTICLES Maria.

ICAR-Directorate of Foot-and-mouth disease, Mukteswar, India

Housekeeping May 1st 31 field trip, transport yourself to the Shady Lakes, pm. PCR results gel is posted (report) This lecture paper discussion.

Viral Diseases How To Diagnose By: Dr. Amr. Viral Diseases How To Diagnose By: Dr. Amr.

KEY CONCEPT Genetics provides a basis for new medical treatments.

KEY CONCEPT Genetics provides a basis for new medical treatments.

Nucleotide sequences encoding part of the VP1 capsid protein of FMDVs derived from infected cattle in phase I and phase II of the study. Nucleotide sequences.

Week 15 Vocab Definitions

Luuk Stooker, DVM Sales Director EMA BioChek

Volume 23, Issue 10, Pages (October 2015)

KEY CONCEPT Genetics provides a basis for new medical treatments.

KEY CONCEPT Genetics provides a basis for new medical treatments.

Volume 10, Issue 2, Pages (August 2011)

US Army Medical Research and Materiel Command

KEY CONCEPT Genetics provides a basis for new medical treatments.

Identification of the recombinant structural proteins expressed in recombinant baculovirus-infected Sf9 cells by immunofluorescence assay with rabbit anti-FMDV.

Presentation transcript:

Enhanced Protection with Inactivated Foot-and-Mouth Disease Virus Purified by a Tagged-Marker Expressing on Virus Surface Animal and Plant Quarantine Agency (QIA), Republic of Korea Jong-Hyeon Park, D.V.M, Ph.D GFRA 2015, HANOI, VIETNAM, OCTOBER 20-22, 2015

Background and Objectives 1.Antigen purification for vaccine preparation by classical methods for differentiation with infected and vaccinated animals (DIVA) is necessary, but expensive and technically difficult. –inserted a hexa-histidine tag (6xHIS) to the VP1 C-terminus for easy purification 2.Needs of a modification of antigen structure for maintaining stable immunity in the field. –replaced two amino acids of VP1/VP2 to enhance the stability on the capsid of the FMD virus (FMDV) Asia1/MOG/05. Checking a protection by lethal challenge in immunized mice with the purified FMDV antigen.

VP1 ~EIIAPEHHHHHHKQ~ 2A 6xHIS Cleavage site VP4 VP2 L VP3 VP1 2B 2C 3A 3B 3C 3D 2A 5’UTR3’UTR O1 Manisa (O/Manisa/Turkey/69) VP4 VP2LVP3VP12B2C3A3B3C3D 2A 5’UTR3’UTR N17DH145Y Asia1/MOG/05 O/manisa/Turkey/69 Materials and Methods Strategy of Virus for Stable and Easy Purification O1M-AsM-P1 VP1 ~EIIAPEHHHHHHKQ~ 2A 6xHIS Cleavage site To evaluate protection using challenge model in mice

Inside view outside view VP2 H145Y VP1 N17D VP1 6xHIS N17D 6xHIS

Plaque assay O1m AsM P1 O1m AsM P1_ N17D H145Y O1m AsM P1_ N17D H145Y_6H Results Stabilized (S)Naïve (N) Stabilized+ Tagged (S, T) in ZZ-R 145 cell

IFDAPIMERGE 6xHIS- FMDV (S,T) Non-6xHIS- FMDV (S) Immunofluorescence for 6X HIS

37 25 kDa Anti-Asia1 VP1 Anti-6x histidine Western Blot O1m AsM P1 O1m AsM P1_ N17D H145Y-6H N S, T

Purification using Histidine-tagged protein purification column (PrepEase ®Histidine Purification Kit) Eluted fraction of 6XHIS tag protein PBM FMDV antigen detection kit Harvest the infected cell and the sup. ↓ BEI inactivation ↓ PEG 6000 ppt ↓ PrepEase ®Histidine Purification ( ≒ 1 hrs)

100nm TEM & IEM (S+T form)

Virus Growth after acid (pH5.5, 6.0, 7.4) treatment for confirmation of stable antigen 30 min treatment N S ST

Challenge after mice immunization with stable non- tagged (S) antigen treated with acid treatment (pH5.5, pH6.0) pH6.0pH5.5 S N S N 0.2 ug antigen with oil adjuvant, ISA week immunization and challenged with 50 LD 50 of Asia1 Shamir

Challenge after mice immunization with stable tagged (S,T) antigen treated with acid treatment (pH 6.0) Non-treatmentpH6.0-treatment ST V C C N

ZZ-R LF-BK BHK21 ZZ-R 4P 6p 8p Sequence variation of 6XHIS through serial passages (O1m_AsM P1_N17D H145Y_6H, ST form ) Z4 Z3 Z4B2 Z4B4 Z4L2 Z4L4 Z6 Z8 Z: ZZR B: BHK21 L: LF-BK PPP R P P P 3 passages

Different positions in VP1 for easy purification VP4 VP2 L VP3VP12B2C3A3B3C3D 2A 5’UTR3’UTR Asia1/MOG/05 O/manisa/Turkey/69 N17DH145Y Asia1 Shamir VP1(150/151) ~ GETTSRRGDMAALA GHHHHHHG QRLSARLPTSFNY VP1(139/140) ~ GET GHHHHHHG TSRRGDMAALAQRLSARLPTSFNY VP1(153/154) ~ GETTSRRGDMAALAQRL GHHHHHHG SARLPTSFNY 6H-139 6H-150 6H-153 VP1 (211/212) -EIIAPEHHHHHHKQ~ 2A O1 AsMS 6H-211

Sequences of 6XHIS in viruses through consecutive passages O1 AsMS- 6H-211 (10p, Z5B5) O1 AsMS 6H-139 (11p, Z5B6) O1 AsMS 6H-153 (11p, Z5B6) O1 AsMS 6H-150 (11p, Z5B6) Z: ZZR B: BHK21

Conclusions 1.Possiblity to easy and simple purification of FMDV antigen within 1 hrs using a commercial metal-affinity column. 2.Obtaining stable 6xHIS-tagged FMDVs sustained under acid conditions (pH 6.0). 3.Vaccination by the purified stable-tagged antigen confer higher protection rate compared to naïve antigen under disassociated condition. 4.The 6XHIS sites would be mutated after serial passages, but the mutation formation depends on the VP1 sequences. 5.The stabilized and tagged antigen offers an alternative to the current methods of antigen purification and enhanced immunity.